CLSA COVID-19 Studies

In response to coronavirus, the CLSA has launched three sub-studies to explore the impacts of the virus.

More than 28,000 CLSA participants have taken part in the CLSA COVID-19 Study to investigate the effects of the pandemic on older adults, exploring how they cope, the impacts on their physical and mental health and changes to how they access health-care services. The questionnaire-based CLSA COVID-19 Study is funded by the Juravinski Research Institute, McMaster University, the McMaster Institute for Research on Aging, the Nova Scotia COVID-19 Health Research Coalition and the Public Health Agency of Canada.

In fall 2020, a partnership with the Government of Canada's COVID-19 Immunity Task Force launched the CLSA COVID-19 Antibody Study. This study collects and analyzes blood samples from more than 19,000 CLSA participants in 10 provinces to better understand how widespread SARS-CoV-2 infection is among adults over age 50. 

A third study, funded by the Canadian Institutes of Health Research and the Weston Brain Institute, examines the impacts of SARS-CoV-2 on brain health.

COVID-19 Antibody Study

The CLSA COVID-19 Antibody Study collects and analyzes blood samples from more than 19,000 CLSA participants in 10 provinces. Study participants also complete a questionnaire, either by phone or online, that collects information about symptoms, risk factors, health-care use and the psychosocial and economic impacts of COVID-19.

Read More